I felt I had to go back to help Gaza's hospitals, says British plastic surgeon
Dr Victoria Rose is a consultant plastic surgeon who worked in Gaza hospitals for two separate periods last year. This is her first-hand story of the war in Gaza.
The word "dire" does not adequately describe the situation in Gaza's hospitals.
On a daily basis when I was working there, I had a list of at least 10 patients, and 60% of them were under the age of 15.
These were tiny children with life-threatening burns and limbs blown off, often losing significant family members in the attacks and left to cope with their life-changing injuries alone.
I first joined the charity IDEALS, which helps medical professionals during crises, in Gaza in 2019. I returned last year, working with orthopaedic surgeons.
I felt compelled to go back after becoming aware that a plastic surgeon from Gaza who trained with me in London had been inundated with complex trauma cases since the war broke out in October 2023.
Our aim was to deliver essential surgical equipment and assist our colleagues with the increasing trauma workload they faced. But as the war progressed, it became apparent that we had a third objective: to bear witness.
I worked at the European Gaza Hospital in March 2024 and then returned in August of that year for a month, working at Nasser Hospital.
The transformation of the landscape during these two visits was staggering. The streets were unrecognisable, just pile after pile of dust and rubble. Such a scale of destruction could only be justified if every single building in Gaza was part of Hamas's infrastructure.
In February 2024, we were denied entry by COGAT – part of the Israel Defence Forces (IDF) controlling activities in the occupied territories – which, regrettably, has become a standard outcome for 50% of foreign doctors attempting to gain access. However, we managed to regain access in May.
This mission was intended to last four weeks at the European Gaza Hospital. However, due to its bombing on the day we arrived and its subsequent decommissioning by the IDF, we were redirected to Nasser for three and a half weeks.
The population had now been relentlessly displaced, bombed in their tents, deprived of water and sanitation, and ultimately starved. I remember thinking it couldn't get any worse – and then they cut the internet.
We ploughed on without essential equipment such as painkillers and antibiotics, patching the patients up, knowing that they were likely to be bombed again.
When we left the hospital we went into the red zone – an area of active fighting that needed to be evacuated.
This meant that nothing could enter without the journey being "deconflicted" by the IDF. Minimal journeys have thus far been deconflicted. Patients struggle to gain entry, and staff cannot leave, as equipment continues to be depleted.
Nasser is the only hospital in the south equipped with a CT scanner, a blood bank, ICU capabilities and an oxygen generator.
I work with two orthopaedic surgeons who run the IDEALS charity. They have been travelling to Gaza since 2009.
IDEALS started the lower limb reconstruction programme in 2013, visiting Gaza every other month and bringing four orthopaedic surgeons back to the UK for short periods of training.
In 2021, I arranged for a plastic surgeon from Gaza to come to London to train with me. He was an incredible trainee and returned to Gaza in February 2023 to take up the post of chief of plastic surgery at Shifa Hospital.
0:54
Shortly after the war broke out, I felt compelled to help him.
All eyes are now on Israel's next move.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
an hour ago
- Sky News
Israel-Iran live: Israeli hospital suffers 'direct hit' as IDF strikes Iranian nuclear reactor
Fighting between Israel and Iran enters a seventh day. A hospital in southern Israel has been hit in an Iranian missile strike, while the IDF bombed a nuclear reactor in southwest of Tehran. Follow the latest and listen to The World as you scroll.
Telegraph
an hour ago
- Telegraph
Battle begins to get blocked Alzheimer's ‘wonder' drugs on NHS
The decision to block Alzheimer's 'wonder' drugs for use by NHS patients will be appealed against. The two breakthrough drugs, proven to slow the onset of Alzheimer's disease, have been rejected for use on the NHS by the National Institute for Health and Care Excellence (Nice). The watchdog chose to stand by its initial decision in final guidance published on Thursday, despite the drugs being approved by the medicines regulator. It means they will only be available privately in the UK. Nice insisted that the benefits were too small to justify the costs involved. Manufacturers of both drugs have confirmed they will now appeal. Bosses behind one of the drugs, donanemab, made by the pharmaceutical firm Lilly, said the system was 'broken' if it 'can't deliver scientific firsts to NHS patients'. Another said the decision 'protects a health service that is not yet ready to identify and manage' Alzheimer's patients. The outcome of the appeal could take up to four months to be reached. Charities described the decision as a 'painful setback' for patients and warned that the 'science was flying by while the system is failing'. Donanemab and lecanemab, the latter manufactured by Eisai, are targeted antibody drugs that slow down the early stages of Alzheimer's. They have been hailed as breakthrough drugs because they target a known cause of the disease – the build-up of a protein in the brain called amyloid – rather than just treating symptoms. Both drugs, delivered via an IV drip, bind to amyloid in the brain and help to clear the buildup and slow down cognitive decline. In clinical trials, donanemab slowed the rate at which memory and thinking get worse by more than 35 per cent, while for lecanemab it was 27 per cent. Results also suggest the drug leads to a slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. However, side effects of the drugs can be serious, including brain bleeds and the risk of death. In its final guidance, Nice recognised that the treatments delay progression of mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Lilly said it would appeal on the grounds that the decision was 'unreasonable' based on the evidence it had submitted. An appeal panel will hear the evidence the company presents, which will include charity and patient testimony, and decide whether to overturn the decision, with a result expected this autumn. Chris Stokes, the president and general manager of UK and northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Gary Hendler, the regional chairman and chief executive of Eisai's European hub, said the company was 'dismayed' and 'very upset about what it means for people with Alzheimer's disease and their families'. 'This decision protects a health service that is not yet ready to identify and manage patients in the early stages of their illness,' he said. 'On top of this, this outcome demonstrates that Nice's appraisal process is simply not fit to evaluate medicines for early Alzheimer's disease. There are currently over 130 new drugs in development for Alzheimer's around the world.' Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. The drugs themselves cost around £20,000 to £25,000 per year, but with the need for regular brain scans and check-ups, the cost to the NHS would likely be between £50,000 and £100,000 per patient, it is understood. 'The science is flying, but the system is failing' Prof Fiona Carragher, the Alzheimer's Society's chief policy and research officer, said the decision was 'highly disappointing'. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease,' she said. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia.' But she said that even if the drugs were approved, 'many patients wouldn't be able to access them because the health system isn't ready to deliver them'. 'The science is flying but the system is failing,' she added, calling on the Government to commit long-term investment to improve early diagnosis rates. Hilary Evans-Newton, the chief executive of Alzheimer's Research UK, said it was 'a painful setback for people affected by Alzheimer's, but sadly not a surprising one'. She added: 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges.' She said it sent a 'troubling signal' to the life science industry and was 'undermining confidence in the UK as a home for research, innovation and clinical trials'. 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments,' she added. 'Lack of long-term evidence' Helen Knight, the director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them.' She said, while the committee accepted any benefits granting 'more time socialising, driving and being independent' would be meaningful, the lack of long-term evidence, 'substantial resources the NHS would need to commit' and risk of displacing other vital services meant it could not be approved. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation,' she added. Drug firms and registered patient groups have until July 8 to appeal against the decision. A reformulation of lecanemab is being developed so it can be administered via an injection under the skin. Nice could then review the drug in this form. Almost one million people in the UK are living with dementia, including one in six over the age of 80. The figure is expected to reach 1.4 million by 2040 as Britain's population ages. Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost-effective.'
Sky News
6 hours ago
- Sky News
I felt I had to go back to help Gaza's hospitals, says British plastic surgeon
Dr Victoria Rose is a consultant plastic surgeon who worked in Gaza hospitals for two separate periods last year. This is her first-hand story of the war in Gaza. The word "dire" does not adequately describe the situation in Gaza's hospitals. On a daily basis when I was working there, I had a list of at least 10 patients, and 60% of them were under the age of 15. These were tiny children with life-threatening burns and limbs blown off, often losing significant family members in the attacks and left to cope with their life-changing injuries alone. I first joined the charity IDEALS, which helps medical professionals during crises, in Gaza in 2019. I returned last year, working with orthopaedic surgeons. I felt compelled to go back after becoming aware that a plastic surgeon from Gaza who trained with me in London had been inundated with complex trauma cases since the war broke out in October 2023. Our aim was to deliver essential surgical equipment and assist our colleagues with the increasing trauma workload they faced. But as the war progressed, it became apparent that we had a third objective: to bear witness. I worked at the European Gaza Hospital in March 2024 and then returned in August of that year for a month, working at Nasser Hospital. The transformation of the landscape during these two visits was staggering. The streets were unrecognisable, just pile after pile of dust and rubble. Such a scale of destruction could only be justified if every single building in Gaza was part of Hamas's infrastructure. In February 2024, we were denied entry by COGAT – part of the Israel Defence Forces (IDF) controlling activities in the occupied territories – which, regrettably, has become a standard outcome for 50% of foreign doctors attempting to gain access. However, we managed to regain access in May. This mission was intended to last four weeks at the European Gaza Hospital. However, due to its bombing on the day we arrived and its subsequent decommissioning by the IDF, we were redirected to Nasser for three and a half weeks. The population had now been relentlessly displaced, bombed in their tents, deprived of water and sanitation, and ultimately starved. I remember thinking it couldn't get any worse – and then they cut the internet. We ploughed on without essential equipment such as painkillers and antibiotics, patching the patients up, knowing that they were likely to be bombed again. When we left the hospital we went into the red zone – an area of active fighting that needed to be evacuated. This meant that nothing could enter without the journey being "deconflicted" by the IDF. Minimal journeys have thus far been deconflicted. Patients struggle to gain entry, and staff cannot leave, as equipment continues to be depleted. Nasser is the only hospital in the south equipped with a CT scanner, a blood bank, ICU capabilities and an oxygen generator. I work with two orthopaedic surgeons who run the IDEALS charity. They have been travelling to Gaza since 2009. IDEALS started the lower limb reconstruction programme in 2013, visiting Gaza every other month and bringing four orthopaedic surgeons back to the UK for short periods of training. In 2021, I arranged for a plastic surgeon from Gaza to come to London to train with me. He was an incredible trainee and returned to Gaza in February 2023 to take up the post of chief of plastic surgery at Shifa Hospital. 0:54 Shortly after the war broke out, I felt compelled to help him. All eyes are now on Israel's next move.
